Importantly, our findings show that a triple combination of BRAFi + MEKi + mTORi inhibited the survival of NR2F1-overexpressing cells in vivo and decreased tumor regrowth rates from MRD, suggesting that mTORi delays tumor growth of DTP cells. This evidence concerns the gene NR2F1 and neoplasm.